Search
News
Downloads
About
Help
Contact
Entity Details
Primary name
NR3L1_HUMAN
Entity type
UniProt
Source
Source Link
Details
Accession
Q68D85
EntryName
NR3L1_HUMAN
FullName
Natural cytotoxicity triggering receptor 3 ligand 1
TaxID
9606
Evidence
evidence at protein level
Length
454
SequenceStatus
complete
DateCreated
2010-01-19
DateModified
2021-06-02
Ontological Relatives
Genes
NCR3LG1
GO terms
Show/Hide Table
GO
Name
GO:0005886
plasma membrane
GO:0016021
integral component of membrane
GO:0050776
regulation of immune response
Subcellular Location
Show/Hide Table
Subcellular Location
Cell membrane
Domains
Show/Hide Table
Domain
Name
Category
Type
IPR003006
Immunoglobulin/major histocompatibility complex, conserved site
Site
Conserved site
IPR003597
Immunoglobulin C1-set
Domain
Domain
IPR003599
Immunoglobulin subtype
Domain
Domain
IPR007110
Immunoglobulin-like domain
Domain
Domain
IPR010999
Retroviral matrix protein
Family
Homologous superfamily
IPR013783
Immunoglobulin-like fold
Family
Homologous superfamily
IPR036179
Immunoglobulin-like domain superfamily
Family
Homologous superfamily
IPR036946
Gamma-retroviral matrix domain superfamily
Family
Homologous superfamily
Diseases
Show/Hide Table
Drugs
Show/Hide Table
Interactions
11 interactions
Interactor
Partner
Sources
Publications
Link
NR3L1_HUMAN
PLPP6_HUMAN
BioGRID, IntAct
32296183
details
NR3L1_HUMAN
TM222_HUMAN
BioGRID, IntAct
32296183
details
NR3L1_HUMAN
CO4A5_HUMAN
BioGRID, IntAct
32296183
details
NR3L1_HUMAN
TM14C_HUMAN
BioGRID, IntAct
32296183
details
NR3L1_HUMAN
NRAC_HUMAN
BioGRID, IntAct
32296183
details
NR3L1_HUMAN
ERG28_HUMAN
BioGRID, IntAct
32296183
details
NR3L1_HUMAN
TTMP_HUMAN
BioGRID, IntAct
32296183
details
NR3L1_HUMAN
TSPO_HUMAN
BioGRID, IntAct
32296183
details
NR3L1_HUMAN
STX8_HUMAN
BioGRID, IntAct
32296183
details
NR3L1_HUMAN
NCTR3_HUMAN
DIP, IntAct
19528259
21422170
21444796
22807449
24275655
27754869
details
NR3L1_HUMAN
TSPOB_HUMAN
BioGRID
32296183
details
This website requires cookies in order to function. By using the site you are agreeing to this as outlined in our
Terms of Use
I Agree